FDA's Psychedelic Bottleneck
The FDA has significantly extended the timeline for psychedelic therapy approvals, rejecting Lykos Therapeutics' MDMA-assisted therapy application in August 2024. The agency, without warning, applied its 2023 draft guidance standards retroactively, scrutinizing the trial's inability to distinguish drug effects from psychotherapy. This retrospective shift has injected deep